Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRXGet Rating) from a hold rating to a buy rating in a research note released on Friday morning.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $2.34 on Friday. Amneal Pharmaceuticals has a 52 week low of $2.15 and a 52 week high of $5.99.

About Amneal Pharmaceuticals

(Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Stories

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.